THERAPY DOSSIER · th-dcba8f56cfca

Soluble JAML (sJAML) and adenoviral fibre knob protein Ad5, both CAR ligands; anti-JAML monoclonal antibody DW100 used in vitro to block JAML-CAR binding

Biologic · Biologic (soluble JAML + adenoviral fibre knob; anti-JAML mAb); no confident ChEMBL match, preclinical

Evidence & regulatory context

Mechanism: Biologic (soluble JAML + adenoviral fibre knob; anti-JAML mAb); no confident ChEMBL match, preclinical
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24621992 ↗2014Reported harm

Neutrophil-derived JAML inhibits repair of intestinal epithelial injury during acute inflammation.

MouseWoundintraperitonealsJAML 20 microgram in 100 microlitre; Ad5 10 microgram in 1…Administered after colonoscopic biopsy wounding, with healing assessed at 2 and…

Model: Superficial colonic mucosal wounds induced by colonoscopic biopsy in mice; 3% DSS (wt/vol) for 5 days used separately to induce colitis

Intraperitoneal sJAML and Ad5 significantly inhibited colonic mucosal wound healing at 4 days after wounding (33 +/- 4.2% and 24.3 +/- 3.1% closure) compared with Ad11 or PBS (65.2 +/- 2.7% and 66.7 +/- 3.2%). The agents given in vivo are injurious CAR ligands; the candidate therapeutic is the bloc…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…